Anti-CD38 antibodies like Daratumumab, Felzartamab, and Isatuximab are an emerging line of new therapeutics for the treatment of multiple myeloma and other cancers. They can lead to a strong interference in indirect antiglobulin tests (IAT) and are a major and increasing challenge for immunohematology laboratories.
Imusyn has developed a new and patented reagent which can overcome anti-CD38 antibody interference in one, simple step. It inhibits the agglutination effect of Daratumumab, Felzartamab, and Isatuximab specifically, without affecting other anti-erythrocyte antibodies like anti-Kell, thus eliminating the need to pre-select donors for compatibility testing.
Imusyn’s proprietary technology masks the CD38 on the surface of the red blood cells (Antigen-masking IAT, AMIAT). The primary component of DaraEx plus is an anti-CD38 antibody without a human Fc region. When treating red blood cells (RBC) with DaraEx plus, the antibody binds CD38, thus covering the epitope of Daratumumab, Felzartamab, and Isatuximab. The DaraEx plus-treated RBC will behave as if no anti-CD38 antibody was present in the sample.